Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Anecdotal reports suggest 25E-NBOH is non-habit-forming, consistent with classical psychedelics. The desire to use it may actually decrease with repeated use.
No lethal dosage has been established for 25E-NBOH, though this does not preclude the possibility of fatal outcomes. Little to no formal research has been conducted on the effects of this substance on humans or animals.
Acute cardiovascular effects including vasoconstriction, elevated blood pressure, and increased heart rate have been reported during intoxication; vasoconstriction contributes to the substance's notable body load, often manifesting as muscle soreness and tension.
Individuals with bipolar disorder or schizoaffective disorder are at elevated risk of experiencing a psychotic episode and are strongly advised to avoid this substance.
Seizures are rarely observed but represent a risk in predisposed individuals, particularly when combined with physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.
25E-NBOH was first synthesized in 2010 by Martin Hansen at the University of Copenhagen, where it was developed as a brain imaging agent for research purposes. The compound was part of a broader effort to create selective serotonin receptor ligands suitable for neuroimaging applications.…
Controlled under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause, which covers structurally related compounds regardless of specific scheduling. Class A classification carries the most severe penalties under UK drug law, including up to seven years imprisonment for possession and life imprisonment for supply offenses.
Not explicitly listed under the Controlled Substances Act of 1970. However, due to structural similarity to NBOMe-class compounds, it may be prosecuted under the Federal Analogue Act of 1986 when sold or possessed for human consumption, effectively treating it as a Schedule I substance. Manufacturing, purchasing, possessing, or distributing without DEA authorization could result in federal prosecution.
14 sources cited
